RecruitingPhase 2NCT07096843

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)

Sponsor

Climb Bio, Inc.

Enrollment

45 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Primary Membranous Nephropathy

Summary

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called budoprutug for people with primary membranous nephropathy. The study is currently recruiting participants at 43 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGbudoprutug

Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183

Locations(43)

Climb Bio Investigative Site #110

Denver, Colorado, United States

Climb Bio Investigative Site #105

Orlando, Florida, United States

Climb Bio Investigative Site #108

Atlanta, Georgia, United States

Climb Bio Investigative Site #106

Indianapolis, Indiana, United States

Climb Bio Investigative Site #111

Boston, Massachusetts, United States

Climb Bio Investigative Site #101

Clifton Park, New York, United States

Climb Bio Investigative Site #104

Sherman, Texas, United States

Climb Bio Investigative Site# 602

Buenos Aires, Argentina

Climb Bio Investigative Site# 603

Buenos Aires, Argentina

Climb Bio Investigative Site #601

CABA, Argentina

Climb Bio Investigative Site #604

CABA, Argentina

Climb Bio Investigative Site #606

Santa Fe, Argentina

Climb Bio Investigative Site #502

Belo Horizonte, Brazil

Climb Bio Investigative Site #505

Minas Gerais, Brazil

Climb Bio Investigative Site #506

Pernambuco, Brazil

Climb Bio Investigative Site #501

Porto Alegre, Brazil

Climb Bio Investigative Site #503

São Paulo, Brazil

Climb Bio Investigative Site #504

São Paulo, Brazil

Climb Bio Investigative Site #701

Temuco, Araucania, Chile

Climb Bio Investigative Site #703

Valdivia, Los Ríos Region, Chile

Climb Bio Investigative Site #702

Santiago, Santiago Metropolitan, Chile

Climb Bio Investigative Site #403

Beijing, Changping District, China

Climb Bio Investigative Site #401

Beijing, Cheng District, China

Climb Bio Investigative Site #408

Shenzhen, Guangdong, China

Climb Bio Investigative Site #402

Wuxi, Jiangsu, China

Climb Bio Investigative Site #407

Xi'an, Shaanxi, China

Climb Bio Investigative Site #405

Jinan, Shandong, China

Climb Bio Investigative Site #409

Yantai, Shandong, China

Climb Bio Investigative Site #404

Yibin, Sichuan, China

Climb Bio Investigative Site #406

Beijing, Xicheng District, China

Climb Bio Investigative Site #903

Tbilisi, Georgia

Climb Bio Investigative Site #902

Tbilisi, Georgia

Climb Bio Investigative Site #901

Tbilisi, Georgia

Climb Bio Investigative Site #204

Taichung, Taiwan

Climb Bio Investigative Site# 202

Taipei, Taiwan

Climb Bio Investigative Site# 201

Taipei, Taiwan

Climb Bio Investigative Site #205

Taipei, Taiwan

Climb Bio Investigative Site# 203

Taipei, Taiwan

Climb Bio Investigative Site #803

Ivano-Frankivsk, Ukraine

Climb Bio Investigative Site# 801

Kyiv, Ukraine

Climb Bio Investigative Site #805

Kyiv, Ukraine

Climb Bio Investigative Site #804

Rivne, Ukraine

Climb Bio Investigative Site #802

Ternopil, Ukraine

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07096843

Related Trials

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275108 locations

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT0757174622 locations

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800104 locations

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT0646613550 locations

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT0569661331 locations